Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 2, 2002, Pages 198-203

  Alexandre, Jérôme ^a,c   Tigaud, Jean Marie ^a   Gross Goupil, Marine ^a   Gornet, Jean Marie ^a   Romain, Didier ^b   Azoulay, Daniel ^a   Misset, Jean Louis ^a   Goldwasser, François ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b Smithkline Beecham   (France)

^c Hôpital Cochin ^*  (France)

Author keywords

Carcinoma; Cirrhosis; Hepatocellular; Oxaliplatin; Topotecan

Indexed keywords

OXALIPLATIN; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG POTENTIATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROPATHY; NEUTROPENIA; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TOPOTECAN;

EID: 0036214843     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200204000-00021     Document Type: Article

References (21)

1. Hepatocellular carcinoma
2. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
3. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin and cisplatin for hepatocellular carcinoma: Effects of hepatitis B and C viral infection on drug toxicity and patient survival
4. Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study
5. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal carcer
6. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
7. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solidtumor cell lines in vitro
8. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin
9. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line
10. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study
11. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function
12. Oxaliplatin. A review of preclinical and clinical studies
13. Topotecan combined with oxaliplatin every 3 weeks in cancer patients: Final results of a phase I study
14. Patient characteristics that predict response and survival after systemic PIAF chemotherapy for inoperable hepatocellular carcinoma
15. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients
16. Intraarterial versus systemic chemotherapy for non-operable hepatocellular carcinoma
17. Metastatic nonresectable fibro lamellar hepatoma: Prognostic features and natural history
18. Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma
19. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma
20. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
21. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma